Paxlovid or Molnupiravir are intended for those with mild to moderate COVID-19, or recent exposure to COVID-19, who are at high-risk for progression to severe COVID-19, and who are within 5 days of symptom onset. Molnupiravir is only for patients for whom other COVID-19 treatment options approved or authorized by the FDA are not accessible or clinically appropriate. Learn more about Paxlovid on the manufacturer’s website, and review the patient and healthcare provider fact sheets for more information. Learn more about Molnupiravir on the manufacturer’s website, and review the patient and healthcare provider factsheets.
People who have had symptoms more than five days, who may be pregnant, or who are not at high risk for severe illness (based on age or medical history), may not be eligible for COVID-19 antiviral treatment through this program.
A virtual visit for COVID-19 antiviral treatment is available to adults and children 12 years and older.
A parent or guardian is required to register someone aged 12 to 18 years old. A parent/guardian must create an account and add a dependent. A parent/guardian can then request a visit for their dependent. If the visit is for your child or adult dependent, you'll both need to be present to see the clinician.
Eligibility may also be restricted depending on your Color program sponsor’s terms. Eligibility through Color’s partnerships with Massachusetts, Washington, Oregon and Wisconsin is limited to persons who are currently located in those states, and pharmacy products are only shipped to valid addresses in Massachusetts, Washington, Oregon and Wisconsin.